

Human MRWCLLLIWAQGLRQAPLAS-GMMTGTIETTGNISAEKGGSIILQCHLSS 49 SEQ ID NO: 1
Rhesus MRWCLFLIWAQGLRQAPLAS-GMMTGTIETTGNISAKKGGSVILQCHLSS SEQ ID NO: 2
Dog MQWYLLLIWAQGLGQAPLPTSGAVSGRIMTMGNISAKEGGSVTLQCHLSS SEQ ID NO: 3
Mouse MHGWLLLVWVQGLIQAAFLATGATAGTIDTKRNISAEEGGSVILQCHFSS SEQ ID NO: 4
TTAQVTQVNWEQQDQ-LLAICNADLGWHISPSFKDRVAPGPGLGLTLQSL 98 SEQ ID NO: 1
TMAQVTQVNWEQHDHSLLAIRNAELGWHIYPAFKDRVAPGPGLGLTLQSL SEQ ID NO: 2
TTANVTQVNWEKQDQ-LLAVHHTDLGWHIYPAFRERVAPGPNLGLTLQSL SEQ ID NO: 3
DTAEVTQVDWKQQDQ-LLAIYSVDLGWHVASVFSDRVVPGPSLGLTFQSL SEQ ID NO: 4
TVNDTGEYFCIYHTYPDGTYTGRIFLEVLESSVAEHGARFQIPLLGAMAA 148 SEQ ID NO: 1
TMNDTGEYFCTYHTYPDGTYRGRIFLEVLESSVAEHSARFQIPLLGAMAM SEQ ID NO: 2
TRNDTGEYLCTYHTYPDGIYRGTFFLEVLQSSVAERSAAFQIPLLGAMAS SEQ ID NO: 3
TMNDTGEYFCTYHTYPGGIYKGRIFLKVQESSVAQFQT---APLGGTMAA SEQ ID NO: 4
TLVVICTAVIVVVALTRKKKALRIHSVEGDLRRKSAGQEEWSPSAPSPPG 198 SEQ ID NO: 1
MLVVICIAVIVVVVLARKKKSLRIHSVESGLQRKSTGQEEQIPSAPSPPG SEQ ID NO: 2
VLAVICVAVILGGLWTRKKKCRRVHCGESGLRTMTYEQEEQSPCILSSTG SEQ ID NO: 3
VLGLICLMVTGVTVLARKK-SIRMHSIESGLGRTEAEPQEWNLRSLSSPG SEQ ID NO: 4
SCVQAEAAPAGLCGEQRGEDCAELHDYFNVLSYRSLGNCSFFTETG 244 SEQ ID NO: 1
SCVQAEAAPAGLCGEQQGDDCAELHDVFNVLSYRSLGSCSFFTETG SEQ ID NO: 2
RAIQVEMVPVGLYTEQRADDYAEPHDYFNVLSYRSLGSFSFLAETG SEQ ID NO: 3
SPVQTQTAPAGPCGEQAEDDYADPQEYFNVLSYRSLESFIAVSKTG SEQ ID NO: 4


FIG. 1

FIG. 2A

FIG. 2B

FIG. 2

FIG. 2A



TIGIT	18	LASGMMTGTIETTGNISAE--KGGSIILQCHLSST---TAQVTQVNWEQQ	62	SEQ ID NO: 5
PVR	22	PPPGTGDVVVQAPTQVPGF--LGDSVTLPCYLQVPNMEVTHVSQLTWARH	69	SEQ ID NO: 6
CD96	18	FVKGVWEKTVNTEENVYAT--LGSDVNLTCQTQTVG----FFVQMQWSKV	61	SEQ ID NO: 7
PVRL2	27	LETGAQDVRVQVLPEVRGQ--LGGTVELPCHLLPP-VPGLYISLVTWQRP	73	SEQ ID NO: 8
PVRL1	24	FLPGVHSQVVQVNDSMYGF--IGTDVVLHCSFANP-LPSVKITQVTWQKS	70	SEQ ID NO: 9
PVRL3	51	RLCGALAGPIIVEPHVTAV--WGKNVSLKCLIEVN----ETITQISWEKI	94	SEQ ID NO: 10
PVRL4	25	FTGRCPAGELGTSDVVTVV--LGQDAKLPCFYRGD--SGEQVGQVAWARV	70	SEQ ID NO: 11
CD226	10	LLHVYRALCEEVLWHTSVP--FAENMSLECVYPSMG----ILTQVEWFKI	53	SEQ ID NO: 12
VSIG2	18	CLSGLAVEVKVPTEPLSTP--LGKTAELTCTYSTS---VGDSFALEWSFV	62	SEQ ID NO: 13
IGSF11	16	TGVAASLEVSESPGSIQVA--RGQTAVLPCTFTTS--AALINLNVIWMVT	61	SEQ ID NO: 14
TREML1	11	LGLEGQGIVGSLPEVLQAP--VGSSILVQCHYRLQ----DVKAQKVWCRF	54	SEQ ID NO: 15
PSG5	26	NFWNLPITAQVTIEALPPKVSEGKDVLLLVHNLPQ-----NLAGYIWYKG	70	SEQ ID NO: 16
SCN1B	16	SACGGCVEVDSETEAVYGM--TFKILCISCKRRSE---TNAETFTEWTFR	60	SEQ ID NO: 17
B7-H4	27	IGFGISGRHSITVTTVASAGNIGEDGIQSCTFEPD--IKLSDIVIQWLKE	74	SEQ ID NO: 18
TIGIT	63	D--Q----LLAICNADLGWHISP--SFKDRVAP-GPGLG----------	92	SEQ ID NO: 5
PVR	70	GESG----SMAVFHQTQGPSYSE----SKRLEFVAARLG-------AELRN	105	SEQ ID NO: 6
CD96	62	TNKID---LIAVYHPQYGFYCAYGRPCESLVTFTETPENGS---------K	100	SEQ ID NO: 7
PVRL2	74	DAPANH-QNVAAFHPKMGPSFPSPKPGSERLSFVSAKQSTGQDTEAELQD	122	SEQ ID NO: 8
PVRL1	71	TNGSK--QNVAIYNPSMGVSVLAP--YRERVEFLRPSFT----------D	106	SEQ ID NO: 9
PVRL3	95	HGKSS--QTVAVHHPQYGFSVQG--EYQGRVLFKNYSLN----------D	130	SEQ ID NO: 10
PVRL4	71	DAGEGA-QELALLHSKYGLHVSP--AYEGRVEQPPPPRN--------P-LD	109	SEQ ID NO: 11
CD226	54	GTQQD---SIAIFSPTHGMVIRKP--YAERVYFLNSTMASN--------N	90	SEQ ID NO: 12


VSIG2 63 QPGKPISESHPILYFTNGHLYPTG-SKSKRVSLLQNPPTVG---------V 103 SEQ ID NO: 13
IGSF11 62 PLSNAN-QPEQVILYQGGQMFDGAPRFHGRVGFTGTMPAT----------N 101 SEQ ID NO: 14
TREML1 55 LPEG-----CQPLVSSAVDRRAPAG----RRTFLTDLGGG----------L 86 SEQ ID NO: 15
PSG5 71 ---Q-----LMDLYHYITSYVVDGQINIYGPAYTGRETVYS----------N 104 SEQ ID NO: 16
SCN1B 61 QKGTEEFVKILRYENEVLQLEEDE-RFEGRVVWNGSRGTKD-------LQD 103 SEQ ID NO: 17
B7-H4 75 GVLG-----LVHEFKEGKDELSEQDEMFRGRTAVFADQVIVG---------N 112 SEQ ID NO: 18
T - F/Y - P - X - G
TIGIT 93 --LTLQSLTVNDTGEYFCIYHTYP--DGAYTGRIFLEVLES---------- 129 SEQ ID NO: 5
PVR 106 ASLRMFGLRVEDEGNYTCLFVTFP--QGSRSVDIWLRVLAKPQNTAEVQK 153 SEQ ID NO: 6
CD96 101 WTLHLRNMSCSVSGRYECMLVLYP--EGIQTKIYNLLIQTHVTADEWNSN 148 SEQ ID NO: 7
PVRL2 123 ATLALHGLTVEDEGNYTCEFATFP--KGSVRGMTWLRVIAKPKNQAEAQK 170 SEQ ID NO: 8
PVRL1 107 GTIRLSRLELEDEGVYICEFATFP--TGNRESQLNLTVMAKPTNWIEGTQ 154 SEQ ID NO: 9
PVRL3 131 ATITLHNIGFSDSGKYICKAVTFP--LGNAQSSTTVTVLVEPTVSLIKGP 178 SEQ ID NO: 10
PVRL4 110 GSVLLRNAVQADEGEYECRVSTFP--AGSFQARLRLRVLVPPLPSLNPGP 157 SEQ ID NO: 11
CD226 91 MTLFFRNASEDDVGYYSCSLYTYP--QGTWQKVIQVVQSDSFEAAVPSN- 137 SEQ ID NO: 12
VSIG2 104 ATLKLTDVHPSDTGTYLCQVNNPPDFYTNGLGLINLTVLVPPSN---P-- 148 SEQ ID NO: 13
IGSF11 102 VSIFINNTQLSDTGTYQCLVNNLPDIGGRNIGVTGLTVLVPPSAPHCQIQ 151 SEQ ID NO: 14
TREML1 87 LQVEMVTLQEEDAGEYGCMVDGAR--GPQILHRVSLNILPPEEEE----- 129 SEQ ID NO: 15
PSG5 105 ASLLIQNVTREDAGSYTLHIIKRGDRTRGVTGYFTFNLYLKLPKP----- 149 SEQ ID NO: 16
SCN1B 104 LSIFITNVTYNHSGDYECHVYRLLFFENYEHNTSVVKKIHIEVVD-KGE- 151 SEQ ID NO: 17
B7-H4 113 ASLRLKNVQLTDAGTYKCYIITSKG-KGNANLEYKTGAFSMPEVNVDYN- 160 SEQ ID NO: 18
V-frame Fingerprint
PVR Family Fingerprint

FIG. 2B



1.400
1.200
1.000
0.800
0.600
0.400
0.200
0.000
Binding (nm)
1
2
3
4
5
6
7
8
TIGIT-Fc
Control-Fc
0
500
1000
1500
2000
2500
Time (Seconds)

FIG. 3



Load hTIGITecd-Fc Bind Ligands at 100 nM
0.6
0.5
0.4
0.3
0.2
0.1
0.0
-0.1
Binding (nm)
PVRL3.ecd-Fc
PVR.sv-Fc
PVRL2.ecd-Fc
PVRL4.ecd-Fc
PVRL1.ecd-Fc
CD96.ecd-Fc
CD226.ecd-Fc
0
100
200
300
400
500
Time (Seconds)

FIG. 4A

FIG. 4B-1	FIG. 4B-2
FIG. 4B-3	FIG. 4B-4
FIG. 4B-5	FIG. 4B-6

FIG. 4B




FIG. 4B-1



Receptor:
CD226
CD96
CHO
CHO-TIGIT
Ligand:
PVRL3
Ligand Binding PE
Receptor Expression

FIG. 4B-2



Receptor:
CHO-PVRL2
CHO-PVR
CHO-CD96
PVRL2
PVR
TIGIT
Ligand:
hIgG1
Ligand Binding PE
Receptor Expression

FIG. 4B-3



Ligand:
PVRL3
CD96
CD226
Receptor:
CHO-PVRL2
CHO-PVR
CHO-CD96
Ligand Binding PE
Receptor Expression

FIG. 4B-4



Ligand:
hIgG1
TIGIT
PVR
PVRL2
Receptor:
CHO-CD226
CHO-PVRL3
Ligand Binding PE
Receptor Expression

FIG. 4B-5



Receptor:
CD226
CHO-CD226
CHO-PVRL3
CD96
Ligand:
PVRL3
Ligand Binding PE
Receptor Expression

FIG. 4B-6



Bound/Total
0.12
0.11
0.10
0.09
0.08
0.07
0.06
0.05
0.04
0.03
0.02
0.01
0.00
10^{-1}
10^{0}
10^{1}
10^{2}
10^{3}
Total (Nanomolar)

FIG. 5A



Bound/Free
0.12
0.10
0.08
0.06
0.04
0.02
0.00
0
80
160
240
320
400
Bound (Picomolar)

FIG. 5B



Receptor:
TIGIT
PVR
CD226
CD96
Ligand:
PVR (0.05 nM)
CD226 (2 nM)
TIGIT (0.1 nM)
PVR (2 nM)
PVR (2 nM)
PVR (2 nM)
% Bound
100
75
50
25
0
Competitor:
0
CD226
0
TIGIT
0
CD226
0
TIGIT
0
TIGIT
0
TIGIT

FIG. 6



CHO-CD226
CHO-TIGIT
PVR Binding

FIG. 7A




CD226-Fc
TIGIT-Fc
Binding (nm)
Time (Seconds)
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
-0.1
0
100
200
300
400
500
600
800

FIG. 7B


Baso
FceR1+
Th0
Th1
Th2
IL6
IL6, TGFb
IL23, a-IL4, a-IFNg
Eff 0h
Eff 15h u
Eff 15h s
Eff 40h s
Eff+Treg 15h u
Eff+Treg 15h s
Eff+Treg 40h s
Treg 0h
Treg+Eff 15h u
Treg+Eff 15h s
Treg+Eff 40h s
0
5000
10000
15000
20000
Normalized TIGIT Expression



Baso
FceR1+
Th0
Th1
Th2
IL6
IL6, TGFb
IL23, a-IL4, a-IFNg
Eff 0h
Eff 15h u
Eff 15h s
Eff 40h s
Eff+Treg 15h u
Eff+Treg 15h s
Eff+Treg 40h s
Treg 0h
Treg+Eff 15h u
Treg+Eff 15h s
Treg+Eff 40h s
0
200
400
600
800
1000
Normalized CD226 Expression

FIG. 8A



10000
1000
100
10
1
ICOS
T_{FH}
14.2
17.3
8.6
14.8
1
10
100
1000
10000
CXCR5
10000
1000
100
10
1
TIGIT
17
52.9
20
10.1
1
10
100
1000
10000
CXCR5
10000
1000
100
10
1
TIGIT
25
44.3
24.5
6.18
1
10
100
1000
10000
ICOS

FIG. 8B



100
80
60
40
20
0
0
10^2
10^3
10^4
10^5

FIG. 9A



GITR
CD4
1.41
0.13
0.11
64.5
33.9
Isotype
FoxP3
0.15
0.16
78.5
21.2
GITR+
TIGIT
1.39
12
42.6
44

FIG. 9B



CD4+CD45RA+
Day 0
Day 1
Day 2
IgG
TIGIT
CD226
CD226/TIGIT
CD4
0
2.39
97.6
7.81e-3
7.1
92.7
0.034
2.56
97.3
0.53
1.77
89.5
1.16
6.29
86.9
0.85
1.43
77.4
7.1e-3
0.043
77.2
4.98
2.14
32.2
2.19
0.31
20.5
8.19
5.7
20.3
22.8
60.7
77

FIG. 10A-1



CD4+CD45RO+
Day 0
Day 1
Day 2
IgG
TIGIT
CD226
CD4
CD226/TIGIT
0.047
92.6
7.33
0.072
91.8
8.04
0.095
98
1.89
6.56
86.6
4.86
23.7
67.7
4.71
38.5
59.9
0.49
66
33.9
0.057
0.038
83.6
7.85
5.9
2.62
91.6
6.32
1.65
0.43

FIG. 10A-2




FIG. 10B




FIG. 10D



CD4+CD45RA+
CD4+CD45RO+
CD4+CD25hiTreg
CD8
NK
TIGIT mRNA Fold Change
TIGIT mRNA Fold Change
D0
D1
D2

FIG. 10C




FIG. 10E




FIG. 10F



TIGIT
CD226
Fold
50.0
40.0
30.0
20.0
10.0
0.0
D0
D1
D2
CD25-
CD25+
CD45RA+
CD45RO+

FIG. 11



Pre-sort
51
46.3
1.47
1.26
TIGIT+
21.3
78.2
0.26
0.21
TIGIT-
3.12
96.7
0
0.21
Resting d5
3.58
95.6
0.27
0.58
1.3
98.1
0.11
0.45
Restim d1
13.6
43
10.6
32.8
5.87
83.4
0.71
10
Restim d2
7.55
91.2
0.14
1.11
4.08
94.7
0.072
1.14
Restim d3
0.41
98.6
6.62e-3
0.98
0.31
98.8
0.016
0.89

FIG. 12A




FIG. 12B




FIG. 13A




FIG. 13B





FIG. 13C

FIG. 14


100
80
60
40
20
0
% of Max
10^0
10^1
10^2
10^3
Alexa 647-A
CCR6-Th1 (CXCR3+)
Th17 (CCR4+CCR6+)
Th2 (CCR4+CCR6-)
CCR6+Th1 (CXCR3+)
100
80
60
40
20
0
% of Max
10^0
10^1
10^2
10^3
Alexa 647-A
Th17
Isotype
Th2




TIGIT
1000
800
600
400
200
0
Norm
Ctrl
Psor
Norm
Crohns
UC
RA
OA
RA
OA
RA
OA
PsoriasisSkin
IBD
Inflamed
Arthritis
Non-Infl
50
40
30
20
10
0
Fibr
Mac
Tcell

FIG. 15


TIGIT Expression in Mouse CIA Model
mRNA Fold Increase Over Normal
20
18
16
14
12
10
8
6
4
2
0
28
35
40
Day



CD226 Expression in Mouse CIA Model
mRNA Fold Increase Over Normal
3.0
2.5
2.0
1.5
1.0
0.5
0.0
28
35
40
Day

FIG. 16




TIGIT
10
8
6
4
2
0
Ctrl
Dis
Baseline
4 Month
8 Month
12 Month
PVR
CD226
5
3
1

FIG. 17


TIGIT Expression
Expression Level
1500
1000
500
0
[N]
[C]
[M]
[D]
Cell Type
[N] Normal
[C] Cancer
[M] Metastasis
[D] Disease (Not Cancer)
p < 0.0001 for comparison between normal and cancer or metastasis



CD4 Expression
Breast Tumors
Expression Level
3000
2000
1000
500
0
CD4
N/A
NO_PCT
<10
10-25
25-50
50-75
75-90
>90

FIG. 18A



TIGIT
Expression Level
1500
1000
500
0
Norm, w/o BC
Norm, w/BC
Norm, M
Fibrocystic
Low Percent
Intraductal
IDC, HER2+
IDC, HER2-
IDC, M
Lobular
IDC and Lobular
Fibroadenoma
Cystosarcoma
Other
Metastatic
LCM, Norm, All
LCM, Norm, Epi
LCM, Duct
LCM, Duct, All
LCM, Duct, Mal
LCM, Duct, F
Expression Level
1500
1000
500
0
N/A
NO_PCT
<10
10-25
25-50
50-75
75-90
>90

FIG. 18B



PVR
Expression Level
800
600
400
200
Norm, w/o BC
Norm, w/BC
Norm, M
Fibrocystic
Low Percent
Intraductal
IDC, HER2+
IDC, HER2-
IDC, M
Lobular
IDC and Lobular
Fibroadenoma
Cystosarcoma
Other
Metastatic
LCM, Norm, All
LCM, Norm, Epi
LCM, Duct
LCM, Duct, All
LCM, Duct, Mal
LCM, Duct, F
Expression Level
800
600
400
200
N/A
NO_PCT
<10
10-25
25-50
50-75
75-90
>90

FIG. 18C




CD226
Expression Level
0
50
100
150
200
250
Norm, w/o BC
Norm, w/BC
Norm, M
Fibrocystic
Low Percent
Intraductal
IDC, HER2+
IDC, HER2-
IDC, M
Lobular
IDC and Lobular
Fibroadenoma
Cystosarcoma
Other
Metastatic
LCM, Norm, All
LCM, Norm, Epi
LCM, Duct
LCM, Duct, All
LCM, Duct, Mal
LCM, Duct, F
Expression Level
0
50
100
150
200
250
N/A
NO_PCT
<10
10-25
25-50
50-75
75-90
>90

FIG. 18D

FIG. 19A






FIG. 19B




FIG. 19C




FIG. 19D




FIG. 20A

FIG. 20B




FIG. 21A




FIG. 21B


FIG. 22A-1

FIG. 22A-2

FIG. 22A-3

FIG. 22A


FIG. 22A-1




IL-12/23p40
TNFα-MDDC
CD40L-MDDC
LPS-MDDC
TLR2-MDDC
pg/ml
2000
1500
1000
500
0
2500
15000
12000
9000
6000
3000
iMDDC
Isotype
TIGIT.Fc
CD226.Fc
TIGIT.DANA

FIG. 22A-2

FIG. 22A-3


IL-12p70
TNFα-MDDC
pg/ml
200
150
100
50
0
CD40L-MDDC
pg/ml
150
100
50
0
LPS-MDDC
pg/ml
600
400
200
0
TLR2-MDDC
pg/ml
200
150
100
50
0
iMDDC
Isotype
TIGIT.Fc
CD226.Fc
TIGIT.DANA



iMDDC
TNFα-MDDC
MFI
HLA-DR
CD80
CD83
CD86
Isotype
TIGIT-Fc
0
50
100
150
200
250
100
200
300
400
500
20
40
60
80
100

FIG. 22B



TNFα-Matured
LPS-Matured
IL-6 pg/ml
2000
1500
1000
500
0
Isotype
TIGIT-Fc
IL-12p70
pg/ml
80
60
40
20
100
75
50
25
IL-18
10
8
6
4
2

FIG. 22C




FIG. 22D




FIG. 23A




FIG. 23B




FIG. 23C




FIG. 24A




FIG. 24B




FIG. 25A




FIG. 25B




FIG. 27A



ILT2
ILT3
ILT5
Isotype
iMDDC
TNF-MDDC Control
TNF-MDDC TIGIT.Fc
% of Max
100
80
60
40
20
0
10^0
10^1
10^2
10^3
10^4

FIG. 26




FIG. 27B




FIG. 27C




FIG. 27D




FIG. 27E




FIG. 27F




FIG. 27G



IL-12p35
CD11c+
IL-12/23p40
CD11c+
IL-10
Relative mRNA Levels
*
0
20
40
60
80
0
1
2
3
4
TIGIT.Fc
Isotype
TIGIT.Fc
Isotype
WT
IL-10.KO
TIGIT.Fc
Isotype
TIGIT.Fc
Isotype
WT
IL-10.KO
TIGIT.Fc
Isotype
TIGIT.Fc
Isotype
CD11c+
CD11c -depleted

FIG. 27H




FIG. 28A




FIG. 28B



Anti-CD3 0.5 μg/ml
+ Anti-CD28
Anti-CD3 5 μg/ml
+ Anti-CD28
siRNAControl
siRNATIGIT
Cell Count
CFSE

FIG. 28C



Anti-CD3 5 μg/ml
Anti-CD3 0.5 μg/ml
siRNAControl
siRNATIGIT
Control
Anti-TIGIT (10A7)
Cell Count
CFSE

FIG. 28D



IL-2
IL-4
IL-10
IFNγ
pg/ml
12000
9000
6000
3000
0
60
40
20
6000
4000
2000
siRNA:
Control
TIGIT

FIG. 28E



Day2
62.8
87.4
Day1
37.1
77.9
Day0
1.3
30.4
CD45RA
CD226
CD45RA
CD226

FIG. 29A




FIG. 29B




FIG. 29C




FIG. 29D




FIG. 29E



Cell Proliferation (cpm)
8000
6000
4000
2000
0
TIGIT.KO
WT
Cell Proliferation (cpm)
12000
10000
8000
6000
4000
2000
0
T Only
T:APC=1:2
TIGIT.KO
WT
**
Cell Proliferation (cpm)
24000
21000
18000
15000
12000
9000
6000
3000
0
TIGIT.KO
WT

FIG. 30A




FIG. 30B



IFNγ (ng/ml)
IL-5 (pg/ml)
TNFα (pg/ml)
IL-4 (ng/ml)
IL-12p70 (pg/ml)
IL-2 (ng/ml)
IL-10 (pg/ml)
TIGIT.KO
WT

FIG. 30C